Opzelura (Ruxolitinib)

Ruxolitinib, the active ingredient in Opzelura, blocks Janus kinase 1 and 2 (JAK1/2). This inhibition interferes with cytokine signaling pathways that drive skin inflammation and abnormal melanocyte activity, thereby reducing inflammatory lesions and supporting pigment restoration.

The specific dose and application frequency of Opzelura are determined by the prescribing clinician based on the patient’s condition, age, and extent of skin involvement. The prescriber will provide individualized instructions for how much cream to apply and how often.

Safety data for Opzelura in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or nursing should discuss risks with their healthcare provider.

To request Opzelura, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, confirming trade or institutional credentials before providing pricing, availability, shipping details, and necessary import documentation.

Opzelura is a topical formulation, whereas many other JAK inhibitors are oral or injectable. The topical route limits systemic exposure, potentially reducing systemic side‑effects compared with oral agents, but it may be less suitable for extensive disease requiring systemic therapy.

Opzelura should be stored at room temperature, preferably below 25 °C. Keep the cream in its original container, protect it from moisture, heat, and direct sunlight, and ensure the cap is tightly closed to maintain product stability.

Opzelura is applied to clean, dry skin. The prescriber will specify the amount of cream to use and the frequency (often twice daily). Gently spread the cream over the affected area, avoiding contact with eyes, mucous membranes, and open wounds unless directed.

Serious risks include secondary skin infections, allergic reactions such as urticaria or angioedema, and rare cases of skin discoloration or malignancy. Patients should promptly report any signs of infection, severe rash, or unexpected changes in skin appearance to their clinician.

Opzelura should not be used by individuals with known hypersensitivity to ruxolitinib or any cream excipients, on infected or severely damaged skin without medical guidance, and by patients receiving systemic JAK inhibitors unless specifically advised by a healthcare professional.